Dr. Reddy’s enters eye care space

David Salazar
Managing Editor
David Salazar profile picture

Having just launched a store brand equivalent to one of the year’s biggest Rx-to-OTC switches, Dr. Reddy's is rolling out its olopatadine hydrochloride ophthalmic solution 0.2% and 0.1%, the equivalents to Alcon’s Pataday Once Daily Relief and Pataday Twice Daily Relief.

The store brand offering from Dr. Reddy’s is indicated to temporarily relieve itchy eyes caused by pollen, ragweed, grass, animal hair and dander. The 0.1% product also is indicated to temporarily relieve red eyes. 

“This launch marks the entry of Dr. Reddy’s into the OTC eye care space and is a testament to our deep capabilities in bringing store-brand equivalents of Rx-to-OTC switches to the U.S. market,” said Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Labs. “We are very excited to extend our strategic collaboration with Gland Pharma to bring these products to the market. We thank the teams at Gland and Dr. Reddy’s whose hard work and efforts have enabled the execution of this launch in such a short timeframe.”

Since the Pataday products made the switch to OTC in March, they have seen U.S. sales of $31 million, according to IRI data. The 0.2% product will be sold in a 2.5-ml bottle and the 0.1% product will be sold in 5-ml bottle sizes.